Tesamorelin

§ Overview

A synthetic analogue of growth hormone-releasing hormone (GHRH) that is FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Tesamorelin is the only GHRH analogue with FDA approval, making it the most clinically validated GH-releasing peptide.

§ Mechanism

Binds to pituitary GHRH receptors, stimulating physiological GH release in a pulsatile pattern. Reduces visceral adipose tissue (VAT) specifically, improves lipid profiles, and may have cognitive benefits through IGF-1 mediated neuroprotection.

§ Common Uses

• → Visceral fat reduction
• → HIV lipodystrophy
• → Body composition
• → Cognitive function
• → Anti-aging

§ Reported Side Effects

• · Injection site reactions
• · Joint pain
• · Peripheral edema
• · Muscle pain
• · Increased blood glucose

§ Research, Experiences & Trends